Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...
The clinical stage biopharmaceutical company is developing inhaled drug delivery devices. Transpire Bio expands headquarters ...
MEMS, wearable/implantable electronics and bio-tissue therapeutics, the pursuit of piezoelectric biomaterials has become a ...
The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo ...
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...
Binance Labs has invested in BIO Protocol, a pioneering protocol transforming the way early-stage scientific research is ...
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
Zacks.com on MSN6h
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue EstimatesBluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago. These figures are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback